About us
At Cambridge Cognition, we aim to improve the health of people around the world by discovering and delivering more effective brain health assessments and methods of administering them at home and in-clinic.
We develop digital technology solutions for cognitive assessments, electronic questionnaires and scales, and decentralised clinical trial solutions. Extraordinary accuracy, scientific discovery and validation are at the core of our business. This means that clinical scientists and academic researchers can trust our products and services to help them to deliver on their study goals and objectives.
Our digital assessments are targeted to specific cognitive domains, with increased data points and reduced noise compared to traditional assessments, making them more sensitive to subtle changes in cognition. For drug development we can help distinguish small effects by different drugs.
Our technology accurately assesses cognition anytime anywhere through mobile, tablet, browser and wearables, using touch and voice functionality.
Our story
The Cambridge Neuropsychological Test Automated Battery (CANTAB®) is developed by Professor Barbara Sahakian and Professor Trevor Robbins at the University of Cambridge.
CANTAB Mobile is launched, a tablet-based cognitive assessment tool for healthcare.
Cambridge Cognition Ltd goes public on the AIM market of the London Stock Exchange.
Winterlight Labs is founded in Toronto, Canada by Frank Rudzicz, Katie Fraser, Liam Kaufman and Maria Yancheva.
Launch of Cognition Kit™ for high-frequency testing on wearable devices such as smartwatches and fitness trackers.
Virtual clinical trial solutions extended including remote patient monitoring, electronic informed consent and online data capture through the acquisition of eClinical Health.
Cambridge Cognition and Winterlight Labs join forces to lead in voice and digital biomarkers for clinical trials.
Who we work with
Supporting academic research through neuropsychological testing technologies, our solutions enable the discovery and enhanced understanding of factors in our biology and environment that affect cognitive function. We have facilitated the advancement of research across the world at top-ranking universities.
We offer a comprehensive solution for assessing cognitive safety and efficacy of drugs in development, from assessment technologies to study delivery. GCP compliant and suitable for use throughout all phases of clinical development, we combine leading scientific software with expert support, trusted by global pharmaceutical companies.
Our suite of healthcare technology solutions are designed to detect the earliest signs of clinically relevant memory problems, measure cognitive performance and assess wellbeing, in primary care and workplace settings, bringing cognitive assessments to patients and employees where they are.
Cambridge Cognition in numbers
indications assessed using our technologies
patients assessed on our digital health tools
peer reviewed papers & articles
patient engagement
Countries
of our customers would recommend us
Meet some of our leaders
Alex Livingstone-Learmonth
Joint Managing Director
![Rob[58] copy](https://cambridgecognition.com/wp-content/uploads/elementor/thumbs/Rob58-copy-q6w2ljmgrba40p23cxhcnsxbdvk5fcfvhgaeds4yfw.png "Rob[58] copy")
Rob Baker
Joint Managing Director
Francesca Cormack
Chief Scientist
Ricky Dolphin
Chief Technology Officer
Maria Yancheva
CTO Winterlight
Nick Taptiklis
Head of R&D Technology
Liam Kaufman
VP Corporate Business Development
Annabelle Miles
Head of Marketing
Careers
We are always looking for the best talent to join our growing team. Learn what it is like to work at Cambridge Cognition and find your next role.
Charity of the Year
